AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dell rises premarket; Tyson Foods, Nordstrom fall
February 6, 2023 8:33 AM ESTBy Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Monday, February 6th. Please refresh for updates.
Dell Technologies (NYSE: DELL) stock rose 1.5% after Bloomberg reported that the tech company was planning on slashing around 6,650 jobs, or about 5% of its global... More
AbbVie (ABBV) looks to new drugs to replace Humiria, lifts deal limit - WSJ
February 6, 2023 7:05 AM ESTAbbVie (NYSE: ABBV) is looking to two newer immune drugs to offset Humira generic competition and is lifting a self-imposed $2 billion limit on the size of potential deals it could be targeting, the Wall Street Journal reported
... MoreAbbvie (ABBV) PT Lowered to $167 at BMO Capital
February 6, 2023 6:39 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Abbvie (NYSE: ABBV) to $167.00 (from $169.00) while maintaining a Outperform rating.... More
Abbvie plans to lift $2 billion cap on deals - WSJ
February 6, 2023 6:35 AM EST(Reuters) - Abbvie will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.
Chief Executive Officer Richard Gonzalez said the company now has the... More
